(CercleFinance.com) – Novartis announced on Tuesday that it will invest $300 million to increase its capabilities in the field of next-generation biotherapeutic drugs.
The Swiss laboratory specifies that its investment project will extend over several years in trades ranging from the production of active substances to the development of new treatments.
In detail, the group intends to invest 100 million dollars within its campus of St. Johann, in Basel, in order to establish a biological platform which will come to supplement its institute of biomedical research (NIBR).
A budget of 110 million dollars will be devoted in parallel to the creation of a ‘biocampus’ located in Menges (Slovenia) to be dedicated to good manufacturing practices (cGMP), non-cGMP processes and technical development.
Finally, the pharmaceutical group has planned to invest some 60 million dollars in its campus in Schaftenau (Austria) in order to develop its production capacities.
Biotherapeutic drugs, sometimes called biological drugs, are composed of basic substances such as amino acids and nucleotides derived from living organisms.
This category of drugs includes in particular monoclonal antibodies and molecules targeting RNA.
Copyright (c) 2022 CercleFinance.com. All rights reserved.